contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


circio-issues-invitation-to-randd-and-corporate-update-webcast-on-24-november-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Circio Holding is a pharmaceutical company. The company's specialist expertise is found in targeted immunotherapy used in the treatment of cancer patients. The company's operations consist of research and development and the medicines are sold under separate brands. Several partnerships in the market have been entered into to strengthen cooperation in the development of new immunotherapy. The company was founded in 2010 and is headquartered in Lysaker.

Circio Holding

CTO Dr. Thomas B Hansen will present a summary of novel circVec in vitro and in vivo results and ongoing R&D activities and plansCEO Dr. Erik D Wiklund will provide a corporate updateOslo, Norway...

<div class="mfn-body"><ul><li>CTO Dr. Thomas B Hansen will present a summary of novel circVec in vitro and in vivo results and ongoing R&amp;D activities and plans</li><li>CEO Dr. Erik D Wiklund will provide a corporate update</li></ul>Oslo, Norway, 17 November 2025 – Circio Holding ASA (OSE: CRNA), a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, issues an invitation to a live webcast at 10:00am CET on Monday 24 November 2025. &nbsp; In the webcast, CTO Dr. Thomas B Hansen will present Circio´s latest&nbsp;in vitro&nbsp;and&nbsp;in vivo&nbsp;results on the circVec circular RNA expression platform. Recent findings include design and testing of novel circVec constructs and extended in vivo screening and validation of circVec for AAV gene therapy. &nbsp; CEO Dr. Erik D Wiklund will provide a general corporate and strategy update. &nbsp; Presenters: CEO Dr. Erik Digman Wiklund CTO Dr. Thomas Birkballe Hansen &nbsp; Time: 10:00 CET on 24 November 2025 &nbsp; <a rel="noopener" href="https://teams.microsoft.com/l/meetup-join/19%3ameeting_MmU0NTBhMTQtZjljMy00ODc4LTk4NzQtNzIwMzQwYTljN2U1%40thread.v2/0?context=%7b%22Tid%22%3a%2266b0661a-3ec3-48a8-a966-5b0cce82b3fe%22%2c%22Oid%22%3a%223f5f84b0-5521-4c04-bd8a-e185546abe04%22%7d">Click here to access Teams webcast</a> Meeting ID: 366 918 860 415 63 Passcode:&nbsp;Kn2Pq9pM &nbsp; Questions can be submitted in advance by email to Erik D Wiklund: <a rel="noopener" href="mailto:erik.wiklund@circio.com">erik.wiklund@circio.com</a> or directly in the live webcast &nbsp; A recording of the webcast will be made available on the <a rel="noopener" href="http://www.circio.com/">Circio webpage</a></div><div class="mfn-footer mfn-contacts mfn-a2287eff07eb">For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: <a rel="noopener" href="mailto:erik.wiklund@circio.com">erik.wiklund@circio.com</a>Lubor Gaal, CFO Phone: +34 683 34 3811 Email: <a rel="noopener" href="mailto:lubor.gaal@circio.com">lubor.gaal@circio.com</a></div><div class="mfn-footer mfn-f39223047539">About Circio Building circular RNA expression systems for enhanced gene and cell therapiesCircio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy.Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&amp;D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden.</div>

Circio issues invitation to R&D and corporate update webcast on 24 November 2025